Flow cytometry is a powerful, emerging technology that can help medical professionals better understand disease, according to Dr. Bill Hanlon, chief scientific officer of Labcorp Drug Development.

FRANKLIN LAKES, N.J., Aug. 9, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp ...

BD is pairing up with Labcorp to develop a new line of companion diagnostics for cancer treatments and therapies for other diseases, analyzing patients’ cells using flow cytometry technology to match ...

Becton Dickinson & Co. and Laboratory Corp. of America Holdings (Labcorp)are teaming up to develop, market and commercialize flow cytometry-based companion diagnostics (CDx) for cancer and other ...

Labcorp is partnering with BD to develop flow cytometry-based companion diagnostics for diseases including cancer. The companies will collaborate with biopharmaceutical partners for exploratory panel ...

Flow cytometry is a way to look closely at the features of cells or particles. A sample of blood or tissue goes into a machine called a cytometer. In less than a minute, a computer can analyze ...

This technology has vast potential to help patients but remains underutilized and underappreciated. The tools are there. What’s lacking are harmonized controls, regulatory guidelines and database ...

One of the primary objectives for the application of flow cytometry in any testing environment should be measurement assurance, i.e., the generation of reliable and reproducible results. This goal can ...